DV
Dividend Vision

DRTS — Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. (DRTS)

Total return is 41.1% over the past 5.4 years, 77.9 points behind SPY at 119.0%. Its deepest 1-year drawdown was 23.9%.

Alpha Tau Medical Ltd. is a clinical-stage oncology company developing diffusing alpha-emitters radiation therapy (Alpha DaRT) for treating solid cancers including skin, oral, pancreatic, prostate, lung, liver, and breast cancer; the technology is currently in clinical trials for multiple cancer types and has a strategic collaboration agreement focused on prostate cancer treatment. The company does not currently have a distribution history. Alpha Tau Medical appeals primarily to growth-oriented investors seeking exposure to early-stage cancer therapeutics development rather than income investors.

DRTS key facts

Asset type
Stock
Asset class
Equity
Inception date
03/08/2021
Distribution frequency
None
Last close
$14.25
Market cap
$1,317,813,632
Average volume
314400.0
Beta
1.185
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.04